EXO, the US, the US state of California, is preparing for a new investment tour. This tour is expected to reach 100 million dollars in total, while the technology giant Samsung is reported to be activated for investment. The South Korean -based company’s initiative capital unit shows special interest in the portable and artificial intelligence -supported ultrasound technology offered by EXO. According to Bloomberg based on anonymous resources, the process between Samsung and EXO is still in the negotiation phase.
Sands Capital, Bold Capital and Qubit Health Capital are the leaders of the new investment tour. It is known that this trio attracted attention with its investments in recent years. On the other hand, the Chairman of the Board of the Chairman of Qubit Health Capital I ISHRAK will participate in the Board of Directors of EXO. Ishrak is a name of Medtronic, a medical device manufacturer for many years.
Founded in 2015, EXO made its name especially with portable ultrasound devices. The device, developed by the company, works with both artificial intelligence and high -precision imaging technologies. These devices, which work by connecting to smartphones, allow health workers to perform patient screening, imaging and reporting through a single application. This system is considered a practical solution for doctors working in the field and emergency intervention teams.
The amount of investment received by the EXO so far has exceeded 320 million dollars. Investors include Intel, Sony, Blackrock, Ra Capital Management and Avidity Partners. The company gathered its biggest investment in 2021 with a series of 220 million dollars C serial C. Now the targeted $ 100 million investment is critical in terms of spreading products and opening to international markets.
Samsung’s interest in EXO may not only be limited to the investment dimension. It is stated that the company also evaluates commercial cooperation with EXO via Samsung Medison, a subsidiary of ultrasound diagnostic devices and digital x -ray systems. This possible cooperation can pave the way for Samsung to expand the medical device ecosystem with more innovative and mobile solutions. EXO’s technology is able to work with existing Samsung products.
In addition, global interest in portable medical devices is increasing every year. The needs that emerged during the period of Pandemi brought faster and on -site diagnosis opportunities to the forefront. The solution offered by EXO is an accessible alternative, especially for health centers in hospitals and rural areas in developing countries. Mobile health solutions are located on the radar of investors due to the potential to have a high impact with low cost.
However, it should be noted that investment negotiations are still not concluded. Samsung did not make a public explanation to the public about the issue, in the same way EXO and other investors reportedly left the questions from the press unanswered. The confidentiality of the negotiations is considered a usual process in such agreements. Therefore, it may take time to clarify the process.
However, there is a general compromise that the technology offered by EXO will contribute to the digital transformation in the health sector. Artificial intelligence -supported analyzes and mobile device integration make health services more efficient and accessible. It is seen that such innovative products are vital especially for low -welded health systems. EXO’s portable device is among the rare solutions that respond to this need.
Samsung’s investment in health technologies is not the first. Previously, the company, which has funded for various health initiatives, continues to focus on the field of digital health. Bonds to be established with companies such as EXO may strengthen their presence in this field. When the new investment tour is completed, the dimensions of this relationship will be seen more clearly.